Vaccination with T cell-defined antigens

Monica C. Panelli, Ena Wang, Vladia Monsurrò, Ping Jin, Katia Zavaglia, Kina Smith, Yvonne Ngalame, Francesco M. Marincola

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Tumour immunology encompasses a broad array of biological phenomena including interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the centre stage because they can be easily demonstrated to specifically recognise autologous cancer cells. As most tumour-associated antigens are intracellular proteins, T cells appear to be the most suitable tool for cancer-specific attack, as anti-bodies do not cross the cell membrane and the innate immune response lacks the same level of specificity. Finally, the relative ease in which T cells can be educated through antigen-specific immunisation to recognise cancer cells has elevated them to an even higher stature. In this review, it will be argued that T cells represent a unique anticancer agent, characterised by absolute specificity. Although other therapeutic modalities (antibody-based) have been effectively implemented, a comparison of T cell-based approaches with other modalities goes beyond the purposes of this review and will not be included in the discussion. However, it is obvious that the role of the T cell is limited and other components of the immune response (effector mononuclear phagocytes, natural killer cells, cytokines, chemokines, soluble factors), genetic background and tumour heterogeneity are likely to be necessary for the completion of cancer rejection.

Original languageEnglish
Pages (from-to)697-707
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume4
Issue number5
DOIs
Publication statusPublished - May 2004
Externally publishedYes

Fingerprint

T-cells
Vaccination
T-Lymphocytes
Antigens
Tumors
Neoplasms
Innate Immunity
Cells
Immunology
Immunization
Biological Phenomena
Adaptive Immunity
Neoplasm Antigens
Cell membranes
Phagocytes
Allergy and Immunology
Chemokines
Natural Killer Cells
Antineoplastic Agents
Cell Membrane

Keywords

  • IL-2
  • Immunisation
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Panelli, M. C., Wang, E., Monsurrò, V., Jin, P., Zavaglia, K., Smith, K., ... Marincola, F. M. (2004). Vaccination with T cell-defined antigens. Expert Opinion on Biological Therapy, 4(5), 697-707. https://doi.org/10.1517/14712598.4.5.697

Vaccination with T cell-defined antigens. / Panelli, Monica C.; Wang, Ena; Monsurrò, Vladia; Jin, Ping; Zavaglia, Katia; Smith, Kina; Ngalame, Yvonne; Marincola, Francesco M.

In: Expert Opinion on Biological Therapy, Vol. 4, No. 5, 05.2004, p. 697-707.

Research output: Contribution to journalReview article

Panelli, MC, Wang, E, Monsurrò, V, Jin, P, Zavaglia, K, Smith, K, Ngalame, Y & Marincola, FM 2004, 'Vaccination with T cell-defined antigens', Expert Opinion on Biological Therapy, vol. 4, no. 5, pp. 697-707. https://doi.org/10.1517/14712598.4.5.697
Panelli MC, Wang E, Monsurrò V, Jin P, Zavaglia K, Smith K et al. Vaccination with T cell-defined antigens. Expert Opinion on Biological Therapy. 2004 May;4(5):697-707. https://doi.org/10.1517/14712598.4.5.697
Panelli, Monica C. ; Wang, Ena ; Monsurrò, Vladia ; Jin, Ping ; Zavaglia, Katia ; Smith, Kina ; Ngalame, Yvonne ; Marincola, Francesco M. / Vaccination with T cell-defined antigens. In: Expert Opinion on Biological Therapy. 2004 ; Vol. 4, No. 5. pp. 697-707.
@article{e670c111ebbe4ad79ad6002d8e85522e,
title = "Vaccination with T cell-defined antigens",
abstract = "Tumour immunology encompasses a broad array of biological phenomena including interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the centre stage because they can be easily demonstrated to specifically recognise autologous cancer cells. As most tumour-associated antigens are intracellular proteins, T cells appear to be the most suitable tool for cancer-specific attack, as anti-bodies do not cross the cell membrane and the innate immune response lacks the same level of specificity. Finally, the relative ease in which T cells can be educated through antigen-specific immunisation to recognise cancer cells has elevated them to an even higher stature. In this review, it will be argued that T cells represent a unique anticancer agent, characterised by absolute specificity. Although other therapeutic modalities (antibody-based) have been effectively implemented, a comparison of T cell-based approaches with other modalities goes beyond the purposes of this review and will not be included in the discussion. However, it is obvious that the role of the T cell is limited and other components of the immune response (effector mononuclear phagocytes, natural killer cells, cytokines, chemokines, soluble factors), genetic background and tumour heterogeneity are likely to be necessary for the completion of cancer rejection.",
keywords = "IL-2, Immunisation, Immunotherapy, Melanoma",
author = "Panelli, {Monica C.} and Ena Wang and Vladia Monsurr{\`o} and Ping Jin and Katia Zavaglia and Kina Smith and Yvonne Ngalame and Marincola, {Francesco M.}",
year = "2004",
month = "5",
doi = "10.1517/14712598.4.5.697",
language = "English",
volume = "4",
pages = "697--707",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Vaccination with T cell-defined antigens

AU - Panelli, Monica C.

AU - Wang, Ena

AU - Monsurrò, Vladia

AU - Jin, Ping

AU - Zavaglia, Katia

AU - Smith, Kina

AU - Ngalame, Yvonne

AU - Marincola, Francesco M.

PY - 2004/5

Y1 - 2004/5

N2 - Tumour immunology encompasses a broad array of biological phenomena including interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the centre stage because they can be easily demonstrated to specifically recognise autologous cancer cells. As most tumour-associated antigens are intracellular proteins, T cells appear to be the most suitable tool for cancer-specific attack, as anti-bodies do not cross the cell membrane and the innate immune response lacks the same level of specificity. Finally, the relative ease in which T cells can be educated through antigen-specific immunisation to recognise cancer cells has elevated them to an even higher stature. In this review, it will be argued that T cells represent a unique anticancer agent, characterised by absolute specificity. Although other therapeutic modalities (antibody-based) have been effectively implemented, a comparison of T cell-based approaches with other modalities goes beyond the purposes of this review and will not be included in the discussion. However, it is obvious that the role of the T cell is limited and other components of the immune response (effector mononuclear phagocytes, natural killer cells, cytokines, chemokines, soluble factors), genetic background and tumour heterogeneity are likely to be necessary for the completion of cancer rejection.

AB - Tumour immunology encompasses a broad array of biological phenomena including interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the centre stage because they can be easily demonstrated to specifically recognise autologous cancer cells. As most tumour-associated antigens are intracellular proteins, T cells appear to be the most suitable tool for cancer-specific attack, as anti-bodies do not cross the cell membrane and the innate immune response lacks the same level of specificity. Finally, the relative ease in which T cells can be educated through antigen-specific immunisation to recognise cancer cells has elevated them to an even higher stature. In this review, it will be argued that T cells represent a unique anticancer agent, characterised by absolute specificity. Although other therapeutic modalities (antibody-based) have been effectively implemented, a comparison of T cell-based approaches with other modalities goes beyond the purposes of this review and will not be included in the discussion. However, it is obvious that the role of the T cell is limited and other components of the immune response (effector mononuclear phagocytes, natural killer cells, cytokines, chemokines, soluble factors), genetic background and tumour heterogeneity are likely to be necessary for the completion of cancer rejection.

KW - IL-2

KW - Immunisation

KW - Immunotherapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=2442674008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442674008&partnerID=8YFLogxK

U2 - 10.1517/14712598.4.5.697

DO - 10.1517/14712598.4.5.697

M3 - Review article

VL - 4

SP - 697

EP - 707

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -